Studies suggest that blockade of AXL may be able to augment EGFR blockade in the setting of tumours with EMT-induced resistance or, potentially, tumours with pre-existing mesenchymal phenotypes21, 24, 35. This evidence concerns the gene AXL and neoplasm.